Torchmark Corporation Announces Third Quarter 2009 Earnings Release and Conference Call
27th October 2009 MCKINNEY, Texas, October 27 /PRNewswire/ -- Torchmark Corporation (NYSE: TMK) will release Third Quarter 2009
earnings after the market closes on Wednesday, October 28, 2009. In
conjunction with...
PRA International to Host Audio Conference:
26th October 2009 RALEIGH, North Carolina, October 26 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces
that its Vice President of Clinical Affairs for Early Development...
Torchmark Corporation Announces Third Quarter 2009 Earnings Release and Conference Call
26th October 2009 MCKINNEY, Texas, October 26 /PRNewswire/ -- Torchmark Corporation (NYSE: TMK) will release Third Quarter 2009
earnings after the market closes on Wednesday, October 28, 2009. In
conjunction with...
Essilor - 2009 Third Quarter Report
22nd October 2009 CHARENTON-LE-PONT, France, October 22 /PRNewswire/ -- Essilor International, the world leader in ophthalmic optics,
today announced its consolidated revenue for the nine months ended September
30,...
Resverlogix Notice of Conference Call & Webcast to Discuss Clinical Trial Data
25th September 2009 CALGARY, Canada, September 25 /PRNewswire/ -- Resverlogix Corp. (TSX:RVX) announced today that it will host a live
teleconference and webcast on Tuesday, September 29, 2009 at 1:00 pm
Eastern/11:00...
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
22nd September 2009 THOUSAND OAKS, California, September 22 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3
'181' trial evaluating Vectibix(R) (panitumumab) in combination with...
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
21st September 2009 THOUSAND OAKS, California, September 21 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3
trial evaluating denosumab administered subcutaneously versus...
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
16th September 2009 THOUSAND OAKS, California, September 16 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced it will present detailed data from
four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34...
Algeta Signs $800 Million (EUR560m) Global Agreement With Bayer for Development and Commercialization of Alpharadin for Bone Metastases
3rd September 2009 OSLO, September 3 /PRNewswire/ --
A Wound that Does Not Heal: Frost & Sullivan Reveals the Impact of Chronic Ulcers on the European Healthcare System
25th August 2009 LONDON, August 25 /PRNewswire/ -- Chronic wounds cause immense suffering, healthcare expenditure, and
disability for millions of patients - and make the wound care market a
billion dollar market....
Amsterdam Molecular Therapeutics Reports Half Year Results 2009
13th August 2009 AMSTERDAM, August 13 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, today reported its results for the first
half year of 2009.
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
5th August 2009 LONDON, August 5 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty
biopharmaceutical company, announces results for the three months to June 30,
2009.
Q2 2009 Financial...
Brand New Conference on Developing 21st Century Military Medical Capabilities to be Held in Abu Dhabi
3rd August 2009 ABU DHABI, UAE, August 3 /PRNewswire/ -- The region's first and only summit on military medicine, Defence
Healthcare 2009 will be held from 22nd - 25th November 2009 at the Hilton
Hotel in Abu...
Radiology Informatics: Frost & Sullivan Examines the Next Big Wave in Medicine
28th July 2009 LONDON, July 28 /PRNewswire/ -- In order to increase productivity, healthcare providers have started to
integrate many IT-based ancillary systems such as EMR, HIS and PACS. So far,
this has purely...
Essilor : First Half 2009 Revenue
17th July 2009 CHARENTON-LE-PONT, France, July 17 /PRNewswire/ --
Allied World Schedules Second Quarter 2009 Earnings Announcement and Conference Call
8th July 2009 PEMBROKE, Bermuda, July 8 /PRNewswire/ -- Allied World Assurance Company Holdings, Ltd (NYSE: AWH) today announced
that it will release its financial results for the second quarter ended June
30,...
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
2nd July 2009 NEW BRUNSWICK, New Jersey and DUBLIN, July 2 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today
announced a definitive agreement whereby Johnson &...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
